# Sitagliptin for the Treatment of Type 2 Diabetes

> **NCT04495881** · PHASE4 · UNKNOWN · sponsor: **Beijing Chao Yang Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Sitagliptin 100mg

## Key facts

- **NCT ID:** NCT04495881
- **Lead sponsor:** Beijing Chao Yang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04495881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04495881, "Sitagliptin for the Treatment of Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04495881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*